Endo debuts generic Duexis

Par, an Endo company, has launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) Duexis.

"We're proud to provide affordable choices to healthcare providers and their appropriate patients while strengthening our reputation as a reliable, quality supplier," said Scott Sims, senior vice president and general manager, injectable solutions and generics at Endo.

The combination medication is used to relieve the signs and symptoms of rheumatoid arthritis and osteoarthritis while decreasing the risk of developing ulcers of the stomach and upper intestines people may experience from ibuprofen alone.

[Read more: Endo confirms reorganization plans]

Ibuprofen-famotidine tablets had a market value of roughly $49 million for the 12 months ended Dec. 31, 2023, per IQVIA.